Integra LifeSciences (IART) Competitors

Integra LifeSciences (NASDAQ:IART) and ICU Medical (NASDAQ:ICUI) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, community ranking, institutional ownership, valuation, dividends and profitability.

Does the MarketBeat Community favor IART or ICUI?

Integra LifeSciences received 53 more outperform votes than ICU Medical when rated by MarketBeat users. However, 64.48% of users gave ICU Medical an outperform vote while only 57.82% of users gave Integra LifeSciences an outperform vote.

Company	Underperform	Outperform
Integra LifeSciences	Outperform Votes 436 57.82%	Underperform Votes 318 42.18%
ICU Medical	Outperform Votes 383 64.48%	Underperform Votes 211 35.52%

Which has more risk & volatility, IART or ICUI?

Integra LifeSciences has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.

Is IART or ICUI more profitable?

Integra LifeSciences has a net margin of 2.63% compared to ICU Medical's net margin of -2.63%. Integra LifeSciences' return on equity of 14.27% beat ICU Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integra LifeSciences	2.63%	14.27%	5.98%
ICU Medical	-2.63%	5.38%	2.58%

Do institutionals & insiders have more ownership in IART or ICUI?

84.8% of Integra LifeSciences shares are owned by institutional investors. Comparatively, 96.1% of ICU Medical shares are owned by institutional investors. 3.1% of Integra LifeSciences shares are owned by insiders. Comparatively, 6.7% of ICU Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Do analysts rate IART or ICUI?

Integra LifeSciences presently has a consensus target price of $35.00, indicating a potential upside of 13.27%. ICU Medical has a consensus target price of $123.00, indicating a potential upside of 15.67%. Given ICU Medical's stronger consensus rating and higher possible upside, analysts plainly believe ICU Medical is more favorable than Integra LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integra LifeSciences	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.10
ICU Medical	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media prefer IART or ICUI?

In the previous week, ICU Medical had 3 more articles in the media than Integra LifeSciences. MarketBeat recorded 8 mentions for ICU Medical and 5 mentions for Integra LifeSciences. Integra LifeSciences' average media sentiment score of 1.19 beat ICU Medical's score of 0.96 indicating that Integra LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integra LifeSciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ICU Medical	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, IART or ICUI?

Integra LifeSciences has higher earnings, but lower revenue than ICU Medical. ICU Medical is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integra LifeSciences	$1.54B	1.58	$67.74M	$0.50	61.80
ICU Medical	$2.26B	1.15	-$29.66M	-$2.45	-43.40

Summary

Integra LifeSciences beats ICU Medical on 11 of the 18 factors compared between the two stocks.